Today's Top SOA Links
From the Wires
Cellular Dynamics International Presents Annual iForumSM Meetings Focused on New Applications and Uses for Differentiated Human iPS Cells
By: Business Wire
Sep. 13, 2017 01:01 PM
Cellular Dynamics International (CDI), a FUJIFILM company, today announced that it will host the iForumSM 2017 meetings at The Buck Institute (Novato, CA) on September 14, 2017, Harvard Medical School (Boston, MA) on September 21, 2017, and at Imperial College (London, U.K.) on September 28, 2017. The annual iForum SM meetings provide attendees with an opportunity to connect with thought leaders from academia, government, biotech, and pharma to discover new applications and innovative uses for differentiated induced pluripotent stem cells (iPSC) through interactive, data-driven presentations.
“iPSCs and differentiated iPSCs have become vital in initiatives directed at disease modeling, drug screening initiatives, toxicity testing, regenerative medicine and more,” said Dr. Bruce E. Novich, Division President-CNBD for FUJIFILM Holdings America Corporation and Division President, Life Science Division of Cellular Dynamics International, a FUJIFILM company. “At the iForumSM 2017 meetings, global leaders in the stem cell community will convene to share how these cells are ushering in a new era of drug and therapeutics discoveries.”
During this premier stem cell event, key opinion leaders will present their insights, investigations, and future plans for utilizing iPSCs in experimental designs. Keynote speakers include:
In addition to educational keynotes from the industry’s leading professionals, the meeting will include scientific talks, poster sessions, and networking. Featured topics will include complex models and regenerative medicine, disease modeling and drug discovery, and predictive toxicology.
For more information or to register to attend one of the iForumSM 2017 meetings, please visit: https://iforum.community/
About Cellular Dynamics International, a FUJIFILM company
Cellular Dynamics International, a FUJIFILM company, is a leading developer and supplier of human cells used in drug discovery, toxicity testing, and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, CDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company’s inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. For more information please visit www.cellulardynamics.com.
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2017, the company had global revenues of $21.5 billion, at an exchange rate of 108 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.
Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week